越鞠丸联合沙库巴曲缬沙坦钠治疗老年心力衰竭合并永久性房颤病人的临床疗效

doi:10.3969/j.issn.1003-9198.2025.10.016

摘要/Abstract

摘要： 目的探讨越鞠丸联合沙库巴曲缬沙坦钠治疗老年永久性房颤合并心力衰竭(心衰)病人的应用效果。方法选取2023年7月至2024年6月宜兴市中医医院收治的100例老年永久性房颤合并心衰病人为研究对象,采用随机数表法将其分为对照组和研究组。对照组给予沙库巴曲缬沙坦钠联合控制心室率治疗,研究组在对照组的基础上加用越鞠丸。比较2组治疗后心功能及疗效的差异。结果研究组的治疗总有效率为92%,显著高于对照组的74%(P<0.05)。与治疗前比较,治疗后2组细胞间黏附分子-1(ICAM-1)、氨基末端脑钠肽前体(NT-proBNP)和促肾上腺皮质激素ACTH水平均显著降低,LVEF水平显著升高,且研究组变化更显著,差异均有统计学意义(P＜0.05)。结论越鞠丸联合沙库巴曲缬沙坦钠在老年永久性房颤合并心衰病人的治疗中具有显著效果,可有效改善病人的心功能,提高生活质量。

关键词: 越鞠丸, 沙库巴曲缬沙坦钠, 老年人, 永久性房颤, 心力衰竭

Abstract: Objective To investigate the effect of Yueju pill combined with sacubitril/valsartan in the treatment of the elderly patients with permanent atrial fibrillation and heart failure. Methods A total of 100 elderly patients with permanent atrial fibrillation and heart failure admitted to Yixing Hospital of Traditional Chinese Medicine from July 2023 to June 2024 were enrolled and randomly divided into two groups by random number table. The control group was given sacubitril/valsartan combined with ventricular rate control therapy. The study group was given Yueju pill on the basis of control group. The cardiac function and efficacy were compared between the two groups. Results The total effective rate of the study group was 92%, which was higher than that of the control group (74%) (P<0.05). After treatment, the serum levels of intercellular adhesion molecule-1 (ICAM-1), N-terminal pro-brain natriuretic peptide (NT-proBNP) and adrenocorticotropic hormone (ACTH)were significantly lower, and the level of left ventricular ejection fraction (LVEF) was higher in the two groups than those before treatment, especially in the study group, and the differences were statistically significant (P< 0.05). Conclusions Yueju pill combined with sacubitril/valsartan is effective in the treatment of the elderly patients with permanent atrial fibrillation and heart failure,which can effectively improve the cardiac function and improve the quality of life.

Key words: Yueju pill, sacubitril/valsartan, aged, permanent atrial fibrillation, heart failure

中图分类号:

袁婷婷, 蒋健聪, 黄达丰, 林松. 越鞠丸联合沙库巴曲缬沙坦钠治疗老年心力衰竭合并永久性房颤病人的临床疗效[J]. 实用老年医学, 2025, 39(10): 1048-1051.

YUAN Tingting, JIANG Jiancong, HUANG Dafeng, LIN Song. Effects of Yueju pill combined with sacubitril/valsartan in the treatment of elderly patients with permanent atrial fibrillation and heart failure[J]. Practical Geriatrics, 2025, 39(10): 1048-1051.

参考文献

[1] 陈孝良, 张银芬, 黄秀峰. 沙库巴曲缬沙坦联合美托洛尔治疗冠心病合并慢性心力衰竭的效果[J]. 临床合理用药, 2024, 17(5): 41-44.
[2] 张舒萌, 常国栋, 康永安. 盐酸阿罗洛尔联合沙库巴曲缬沙坦钠治疗心力衰竭的临床研究[J]. 现代医药卫生, 2024,40(2): 237-240.
[3] 牛洁婷, 王文娟, 赵莉, 等. 沙库巴曲缬沙坦钠治疗急性心肌梗死PCI术后心力衰竭患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(2): 160-164.
[4] 陈慧, 欧阳秋芳, 郭进建, 等. 健心颗粒联合沙库巴曲缬沙坦钠片对心力衰竭大鼠心功能和左室重构的影响[J]. 山西中医, 2024, 40(1): 56-58.
[5] 张瀚文, 于嘉祥, 石岩, 等. 基于肝脏TMT标记定量蛋白质组学技术研究越鞠丸防治“双心疾病”的作用机制[J]. 中国实验方剂学杂志, 2023, 29(1): 26-36.
[6] 许顶立, 宋霖. 《中国心力衰竭诊断和治疗指南2024》解读[J]. 临床心血管病杂志, 2024, 40(6): 437-439.
[7] 高洁, 燕建锋, 方舒, 等. 永久起搏器程控在心房颤动诊断中的临床应用及意义[J]. 现代生物医学进展, 2023,23(6): 1100-1104.
[8] 郑海波. 补阳活血汤联合沙库巴曲缬沙坦钠片治疗阳气亏虚血瘀型慢性心力衰竭急性加重期临床研究[J]. 新中医, 2023, 55(23): 35-40.
[9] 赵佳婧, 陆曙, 彭健. 基于病案分析陆曙教授使用越鞠丸治疗心血管疾病的药物加减及合方规律[J]. 医学信息, 2023, 36(6): 20-24.
[10] 姚渊, 邱复亮, 顾方方. 安定汤加味联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭41例[J]. 中国中医药科技, 2023, 30(6): 1229-1231.
[11] HUANG X M, LI J J, YIN W, et al. Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study[J]. BMC Cardiovasc Disord, 2024, 24(1): 79.
[12] KANG D W, KANG S H, LEE K, et al. Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: systematic review and network meta-analysis[J]. Int J Cardiol, 2024, 400: 131786.
[13] OLIVEROS E, GRAPSA J. Finding new echocardiographic parameters for reverse cardiac remodeling: isovolumic contraction velocity in heart failure with reduced ejection fraction and effect of sacubitril/valsartan: the PROVE-HF study[J]. J Card Fail, 2024, 30(5): 666-668.
[14] SHULZHENKO L V, PERSHUKOV I V, BATYRALIEV T A, et al. The clinical evolution of diffuse myocardial fibrosis in patients with arterial hypertension and heart failure with mildly reduced ejection fraction treated by olmesartan or sacubitril/valsartan[J]. Kardiologiia, 2023, 63(12): 31-38.

[1]	王美娟, 姜学忠, 王屹. 老年人深静脉血栓治疗进展[J]. 实用老年医学, 2025, 39(9): 865-870.
[2]	张一丹, 杨建, 刘姣, 李霞, 龚黎, 姚静. 老年人深静脉血栓的影像学诊断进展[J]. 实用老年医学, 2025, 39(9): 871-875.
[3]	杜海雯, 张一丹, 李霞, 刘姣, 魏淑萍. 老年人深静脉血栓的流行病学与危险因素研究进展[J]. 实用老年医学, 2025, 39(9): 879-882.
[4]	章雨雯, 陈立建. 晶体预扩容和胶体预扩容对老年病人无痛肠镜血流动力学和术后早期认知功能的影响[J]. 实用老年医学, 2025, 39(9): 894-898.
[5]	朱承媛, 路悦, 郏文亭, 黄悦, 林枫, 张丽霞. 探讨健康老年人基于失语症语料任务的会话特征[J]. 实用老年医学, 2025, 39(9): 899-903.
[6]	黄涌, 王锋锋, 石伯生, 黄丽, 王志飞. 经皮穴位电刺激对老年髋部骨折病人术后疼痛管理及胃肠功能恢复的影响[J]. 实用老年医学, 2025, 39(9): 910-914.
[7]	吕文君, 康静, 莫非. 健康生态学视角下中国老年人日常活动能力现状及影响因素研究[J]. 实用老年医学, 2025, 39(9): 915-919.
[8]	闫振龙, 黄萍, 陈蒙, 陶俊杰, 王玉川, 陈丽莉, 范雅, 李泽华, 周小恬. 中文版老年人风险识别量表的修订及在急诊病人中的信效度验证[J]. 实用老年医学, 2025, 39(9): 920-923.
[9]	张宁, 高秀, 康琳, 刘晓红. 17例老年肺放线菌感染病人临床特征分析[J]. 实用老年医学, 2025, 39(9): 924-928.
[10]	莫军, 张思平, 张焕文, 李建江, 丹尼尔·阿不力米提, 黄异飞. 选择性椎体成形术治疗多节段骨质疏松性椎体骨折的疗效观察[J]. 实用老年医学, 2025, 39(9): 929-932.
[11]	姚贺玲, 王余, 李宛凇, 骆泓洁, 吕晓磊, 王欣, 冯丽娜. 老年脑小血管病脑白质高信号对膀胱过度活动症的临床价值[J]. 实用老年医学, 2025, 39(9): 933-936.
[12]	姚远, 杨勇. 免疫衰老在老年非小细胞肺癌中的作用机制研究进展[J]. 实用老年医学, 2025, 39(9): 947-951.
[13]	周丹, 魏可欣, 邓姝, 何锐. 人工智能与可穿戴设备在老年人静脉血栓栓塞防治中的研究进展[J]. 实用老年医学, 2025, 39(9): 963-967.
[14]	何欣欣, 谢冬梅, 王晓玲, 李颖, 高浪丽. 人工智能在失能老年人照护中的应用研究进展[J]. 实用老年医学, 2025, 39(8): 757-761.
[15]	江会增, 刘金娜, 张丹丹, 张洁. 人工智能在老年人跌倒风险管理中的应用进展[J]. 实用老年医学, 2025, 39(8): 762-767.